NO20014508D0 - Fremgangsmåte for acylering av peptider, og nye acyleringsmidler - Google Patents

Fremgangsmåte for acylering av peptider, og nye acyleringsmidler

Info

Publication number
NO20014508D0
NO20014508D0 NO20014508A NO20014508A NO20014508D0 NO 20014508 D0 NO20014508 D0 NO 20014508D0 NO 20014508 A NO20014508 A NO 20014508A NO 20014508 A NO20014508 A NO 20014508A NO 20014508 D0 NO20014508 D0 NO 20014508D0
Authority
NO
Norway
Prior art keywords
acylating
new
peptides
agents
acylating agents
Prior art date
Application number
NO20014508A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014508L (no
Inventor
Louis Brammer Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20014508L publication Critical patent/NO20014508L/no
Publication of NO20014508D0 publication Critical patent/NO20014508D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014508A 1999-03-17 2001-09-17 Fremgangsmåte for acylering av peptider, og nye acyleringsmidler NO20014508D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99610019 1999-03-17
PCT/DK2000/000117 WO2000055119A1 (fr) 1999-03-17 2000-03-16 Methode d'acylation de peptides et nouveaux agents d'acylation
EP00910573A EP1163211B1 (fr) 1999-03-17 2000-03-16 Methode d'acylation de peptides et proteines

Publications (2)

Publication Number Publication Date
NO20014508L NO20014508L (no) 2001-09-17
NO20014508D0 true NO20014508D0 (no) 2001-09-17

Family

ID=26074622

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014508A NO20014508D0 (no) 1999-03-17 2001-09-17 Fremgangsmåte for acylering av peptider, og nye acyleringsmidler

Country Status (16)

Country Link
EP (2) EP1163211B1 (fr)
CN (1) CN1344248A (fr)
AT (1) ATE409193T1 (fr)
AU (1) AU3273500A (fr)
BR (1) BR0009040A (fr)
CA (1) CA2361830A1 (fr)
CZ (1) CZ20013018A3 (fr)
DE (1) DE60040333D1 (fr)
ES (1) ES2315226T3 (fr)
HU (1) HUP0200297A3 (fr)
IL (1) IL144989A0 (fr)
NO (1) NO20014508D0 (fr)
PL (1) PL351326A1 (fr)
RU (1) RU2001128068A (fr)
WO (1) WO2000055119A1 (fr)
ZA (1) ZA200106884B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
PL367687A1 (en) * 2001-07-24 2005-03-07 Novo Nordisk A/S Method for making acylated polypeptides
JP2005503141A (ja) * 2001-07-24 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ アシル化ポリペプチドを作出するための方法
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
HUP0501192A3 (en) * 2001-08-23 2006-06-28 Lilly Co Eli Glucagon-like peptide-1 analogs
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004029081A2 (fr) * 2002-09-25 2004-04-08 Theratechnologies Inc. Peptides glp-1 modifies a activite biologique accrue
ATE434602T1 (de) * 2002-09-25 2009-07-15 Novo Nordisk As Verfahren zur herstellung acylierter peptide
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
CN1812808B (zh) 2003-06-03 2012-07-04 诺沃挪第克公司 稳定化的药物肽组合物
BRPI0410972C1 (pt) 2003-06-03 2021-05-25 Novo Nordisk As método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
DK1687019T3 (en) 2003-11-20 2018-02-12 Novo Nordisk As Propylene glycol peptide formulations that are optimal for production and use in injection devices
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
WO2006037811A2 (fr) 2004-10-07 2006-04-13 Novo Nordisk A/S Composes d'exendin-4 a action prolongee
BRPI0517341A (pt) 2004-11-12 2008-10-07 Novo Nordisk As composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
EP2280993A1 (fr) 2008-05-15 2011-02-09 Novo Nordisk A/S Purification de peptides préparés par synthèse en phase solide
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
NZ603169A (en) 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
CA2802510A1 (fr) 2010-06-23 2011-12-29 Novo Nordisk A/S Derives d'insuline contenant des liaisons disulfure supplementaires
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
EA201390796A1 (ru) 2011-01-20 2014-07-30 Зилэнд Фарма А/С Применение ацилированного аналога глюкагона
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
EP2707713A2 (fr) 2011-05-10 2014-03-19 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
CA2853884A1 (fr) 2011-11-03 2013-05-10 Zealand Pharma A/S Conjugues de peptide agoniste du recepteur du glp-1 et de gastrine
CA2872314C (fr) 2012-05-03 2021-08-31 Zealand Pharma A/S Composes agonistes doubles du gip-glp-1 et methodes
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR20150096433A (ko) 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제
HRP20211911T1 (hr) 2013-03-15 2022-03-18 Protagonist Therapeutics, Inc. Analozi hepcidina i njihova uporaba
CN105377306B (zh) 2013-06-20 2020-03-17 诺和诺德股份有限公司 Glp-1衍生物和其用途
KR20160029079A (ko) 2013-07-04 2016-03-14 노보 노르디스크 에이/에스 Glp-1 유사 펩티드의 유도체 및 그것의 사용
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
EP3080150B1 (fr) 2013-12-13 2018-08-01 Sanofi Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN104558097A (zh) * 2014-05-20 2015-04-29 广东东阳光药业有限公司 肽的酰化方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CA2955460A1 (fr) 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Peptides inhibiteurs par voie orale du recepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
EP3201217A4 (fr) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine
CA2965732A1 (fr) 2014-10-29 2016-05-06 Zealand Pharma A/S Composes agonistes de gip et procedes associes
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
WO2016097108A1 (fr) 2014-12-17 2016-06-23 Novo Nordisk A/S Dérivés de glp-1 et utilisations associées
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (fr) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree
EP3205660A1 (fr) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Procédé de préparation de peptides à liaison pswang
EP3196206A1 (fr) 2016-01-20 2017-07-26 Lonza Ltd Procédé de préparation de liraglutide
US11236123B2 (en) 2016-01-20 2022-02-01 Polypeptide Laboratories Holding (Ppl) Ab Method for preparation of peptides with psWang linker
EP3205664A1 (fr) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Procédé de préparation de liraglutide utilisant un lieur bal
WO2017165676A1 (fr) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. Procédés de synthèse d'antagonistes de peptide α4β7
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018083335A1 (fr) 2016-11-07 2018-05-11 Novo Nordisk A/S Esters à dchbs actif de composés peg et leur utilisation
EP4129321A1 (fr) 2016-12-05 2023-02-08 Nuritas Limited Compositions comprenant le peptide wkdeagkplvk
EP3329930A1 (fr) 2016-12-05 2018-06-06 Nuritas Limited Compositions pharmaceutiques
WO2018103868A1 (fr) 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acylés
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂
WO2018104558A1 (fr) 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acylés
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
CA3073806A1 (fr) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Peptides d'agoniste opioide et leurs utilisations
CA3089868A1 (fr) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Mimetiques d'hepcidine conjugues
EP3759120A1 (fr) 2018-02-27 2021-01-06 Zp Spv 3 K/S Analogues de compstatine et leurs utilisations médicales
WO2020127476A1 (fr) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Composition pharmaceutique comprenant un analogue de glp -1
CN111909073A (zh) * 2019-05-10 2020-11-10 江苏万邦医药科技有限公司 一种制备高纯度脂肪酸衍生物的方法
CA3146390A1 (fr) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
BR112022003760A2 (pt) 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos
WO2021059075A1 (fr) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anticorps anti-ceacam et leurs utilisations
WO2021123228A1 (fr) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Composition pharmaceutique comprenant un analogue de glp-1
EP4090670A1 (fr) 2020-01-15 2022-11-23 Janssen Biotech, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도
EP4126004A1 (fr) 2020-03-30 2023-02-08 Zealand Pharma A/S Combinaison d'agonistes
EP4126003A1 (fr) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2
CA3202226A1 (fr) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions d'inhibiteurs peptidiques du recepteur de l'interleukine-23
EP4281039A2 (fr) 2021-01-25 2023-11-29 Mylan Ireland Limited Compositions peptidiques pharmaceutiques et leurs procédés de préparation
TW202315882A (zh) 2021-09-03 2023-04-16 丹麥商西蘭製藥公司 給藥方案
WO2024061919A1 (fr) 2022-09-19 2024-03-28 Zealand Pharma A/S Polythérapie
WO2024068848A1 (fr) 2022-09-28 2024-04-04 Zealand Pharma A/S Méthodes de traitement de l'obésité

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
WO1998002460A1 (fr) 1996-07-11 1998-01-22 Novo Nordisk A/S Procede selectif d'alcylation
AU4112497A (en) * 1996-08-30 1998-03-19 Novo Nordisk A/S Glp-2 derivatives
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
WO1999043708A1 (fr) 1998-02-27 1999-09-02 Novo Nordisk A/S Derives de gpl-1 et de l'extendine au profil d'action etendu

Also Published As

Publication number Publication date
NO20014508L (no) 2001-09-17
PL351326A1 (en) 2003-04-07
ES2315226T3 (es) 2009-04-01
CZ20013018A3 (cs) 2002-02-13
CA2361830A1 (fr) 2000-09-21
RU2001128068A (ru) 2004-02-20
EP1956000B1 (fr) 2016-10-05
CN1344248A (zh) 2002-04-10
WO2000055119A1 (fr) 2000-09-21
AU3273500A (en) 2000-10-04
DE60040333D1 (de) 2008-11-06
EP1163211B1 (fr) 2008-09-24
ATE409193T1 (de) 2008-10-15
HUP0200297A3 (en) 2002-09-30
IL144989A0 (en) 2002-06-30
ZA200106884B (en) 2002-03-01
BR0009040A (pt) 2001-12-18
HUP0200297A2 (en) 2002-06-29
EP1956000A1 (fr) 2008-08-13
EP1163211A1 (fr) 2001-12-19

Similar Documents

Publication Publication Date Title
NO20014508L (no) Fremgangsmåte for acylering av peptider, og nye acyleringsmidler
CA2270289A1 (fr) Proteines a concentration amelioree en acides amines essentiels
DE69713112T2 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
ATE254138T1 (de) An den erythropoietin-rezeptor bindende zusammensetzungen und peptide
HU9200548D0 (en) Improved activity process of recombined proteins
ATE321774T1 (de) An aminosaeure angereicherte speicherproteine, insbesondere an lysin angereicherte mais-gamma- zeine, und diese exprimierende pflanzen
BR0010720A (pt) Peptìdeos de neisseria antigênicos
DE69129865D1 (de) Osteogene peptide
FI880017A (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
SE8801701D0 (sv) Production technology based on enzymic method
ITMI951764A0 (it) Peptide sintetasi ingegnerizzate e loro impiego per la produzione via non-ribosomale di peptidi
PT896615E (pt) Peptido proveniente de uma forma soluvel de acetilcolinesterase activo como modulador dos canais de calcio
EP0716591A4 (fr) PROCEDES ET COMPOSITIONS DESTINES A FIXER DES PROTEINES TAU ET MAP2c
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
EP1132402A4 (fr) Fragments peptidiques a activite inhibitrice de la mort cellulaire
WO2003002730A3 (fr) Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode
DE3852105T2 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
DE60229883D1 (de) Biologisch aktive peptide
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
DK0975742T3 (da) Aminopeptidase, der stammer fra Bacillus licheniformis og fremgangsmåde til fremstilling af et natur-type proteiner
DE60120357D1 (de) Haemophilus influenza äusseres membranprotein und verwendung davon als impstoff
TH17162A (th) สารผสมฟอกจากที่ประกอบด้วยเอนไซม์โพรทีเอส
WO2004011491A3 (fr) Polypeptides purifies d'enterococcus faecalis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application